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A B S T R A C T
Purpose: Erectile dysfunction (ED) is common in males with epilepsy, likely of multifactorial etiology,
including possible systemic vascular comorbidities and medication effects. Here we examined male
patients for the possibility of a vasculogenic element of ED.
Methods: Research participants included 47 men with epilepsy (mean age = 30.98 years; duration of
illness = 13.98 years) and 25 healthy matched men (mean age = 30.36). Erectile function was assessed
using the International Index of Erectile Function Questionnaire (IIEF-5). Penile blood ﬂow was assessed
using Duplex Ultrasonography (PDU) after intracavernous alprostadil injection. Penile peak systolic
velocity (PSV), end-diastolic velocity (EDV) and resistance index (RI) were the functional parameters
analyzed. Carotid artery intima media thickness (CA-IMT) was also measured.
Results: Thirteen of the 47 men with epilepsy (23.40% versus 0% for controls) reported ED, and of these
patients, 11 (84.62%) had abnormal PDU [PSV = 28.23  6.1 cm/s, P = 0.0001; EDV = 2.22  5.71 cm/s,
P = 0.004; RI = 0.89  0.22, P = 0.071] suggesting vasculogic ED. Penile arterial insufﬁciency was identiﬁed in
5 (45.45%), while 6 (54.54%) had mixed arterial insufﬁciency and venous leak. Compared to patients with
high PSV, patients with low PSV had lower IIED-5 scores, higher EDV, lower RI, higher diastolic blood pressure
and higher CA-IMT values. There were no differences in depression, anxiety or concentrations of sex
hormones. Signiﬁcant correlations were evident between PDU variables and duration of illness, depression
and anxiety scores and CA-IMT values. In multivariate analysis, the association between PDU parameters and
CA-IMT values remained signiﬁcant even after adjustment for other confounding variables.
Conclusions: Vasculogenic ED is frequent with epilepsy and its relationship to systemic atherosclerosis
cannot be excluded.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Epilepsy is a major public health problem.1 In the general
population, the prevalence of epilepsy is estimated to be 8.2/1000,Abbreviations: ED, erectile dysfunction; AEDs, antiepileptic drugs; IIEF-5, Interna-
tional Index of Erectile Function -5 item version; PDU, Penile Duplex Ultrasonog-
raphy; PSV, peak systolic velocity; EDV, end-diastolic velocity; RI, resistance index;
CA-IMT, carotid artery intima media thickness; BDI-II, Beck Depression Inventory
(2nd edition); HAM-A, Hamilton Anxiety Rating Scale; SHBG, sex hormone binding
globulin.
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1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights rethe prevalence even higher in developing countries (10–12.9/
1000) (e.g., Colombia, Ecuador, Egypt India, Nigeria, United
Republic of Tanzania and Venezuela).2,3 Abnormalities in sexual
function are common comorbid conditions in patients with
epilepsy with a nearly ﬁve-fold increased risk compared to the
general population.4 Erectile dysfunction (ED), deﬁned as a
persistent or recurrent partial or complete failure to obtain and/
or maintain penile erection until the end of sexual activity, has
been estimated to occur in 50–66% of men with epilepsy.5 The
etiology of ED in men with epilepsy is likely multifactorial,
including several categories of risk factors: (a) neuro-endocrino-
logical factors due to abnormalities in the hypothalamic–pitui-
tary–adrenal axis and sex steroid hormones potentially caused by
epileptic discharges, particularly of temprolimbic origin,6–8 (b)served.
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antiepileptic drugs (AEDs), particularly enzyme-inducing AEDs
(EI-AEDs) [i.e. carbamazepine (CBZ), phenytoin (PHT) and pheno-
barbital (PB)],9–11 (c) psychosocial factors including depression
and anxiety,12–17 and (d) vasculogenic considerations due to
vascular risk factors or atherosclerotic changes associated with
epilepsy.18–32 Vascular comorbidities with epilepsy are not
uncommon. However, the possibility of vasculogenic ED with
epilepsy is very understudied but may represent a signiﬁcant
consideration due to the fact that chronic epilepsy and its long-
term treatment, particularly with EI-AEDs, has been found to be
associated with adverse vascular proﬁles including increased levels
of von Willbrand factor (vWF), ﬁbrinogen and oxidized low density
lipoprotein (Ox-LDL),26 hypercholesterolemia/dyslipidemia,19,24,27
increases in various lipid fractions such as lipoprotein(a) (Lpa),19
hyperhomocysteinemia (HHcy),20,22,23,26.32 hyperuricemia,22
hyperinsulinemia and insulin resistance,27,28 hyperleptinemia and
leptin resistance,27,28weight gain and metabolic syndrome.21,25,26,31
Chronic epilepsy has also been found to be associated with
signiﬁcantly increased carotid artery intima-media thickness
(CA-IMT),23,26,30 higher rates of early death from ischemic heart
disease18 and cerebrovascular stroke,31 and (e) a combination of
these etiologies.
In general, a normal full erection is deﬁned as an erection to
more than 908 that is ﬁrm to palpation. It is achieved within 15 min
and lasts longer than 15 min. Normal erection involves relaxation
of the smooth musculature of the cavernous tissue and penile
arteriolar and arterial walls resulting in: (a) an increase in the
blood ﬂow in both diastolic and systolic phases due to arteriolar
and arterial wall dilatation, and (b) venous compression due to
trapping of the incoming blood by the expanding sinusoids and
compression of the subtunical venular plexuses between the
tunica albuginea and the peripheral sinusoids. These reduce the
venous outﬂow and stretch the tunica to its capacity which
encloses the emissary veins between the inner circular and the
outer longitudinal layers with further decrease in the venous
outﬂow to a minimum. These changes increase the intracavernous
pressure (maintained at around 100 mm Hg) and raise the penis
from the dependent position to the erect state (the full-erection
phase). A further increase in pressure to several hundred
millimeters of mercury results in contraction of the ischiocaver-
nosus muscles and this produces the rigid-erection phase.5
The hemodynamic of erection in normal and disease states can
be determined using Penile Duplex Ultrasonography (PDU). PDU
has been widely used to determine and document the presence of
penile arterial insufﬁciency, inﬂow or outﬂow types of ED, venous
leak, signs of atherosclerosis and scarring or calciﬁcation of erectile
tissue, in order to predict the response of ED to medications.
Various parameters, such as the diameter of the cavernosal artery,
peak systolic ﬂow velocity (PSV) and the degree of arterial
dilatation and acceleration time, have been suggested for the
diagnosis of arteriogenic ED, while end-diastolic ﬂow velocity
(EDV) and resistance index (RI) have been suggested for the
diagnosis of venous leak. RI is estimated by subtracting PSV from
EDV and divided by PSV.5,33
PDU can be used to assess penile blood ﬂow in men with
epilepsy. PDU spectral wave analysis during full erection obtained
after intracavernous injection of vasoactive substance (e.g.
prostaglandin E1, or PGE1) has been considered to be the more
accurate, most reliable and least invasive evidence-based diagnos-
tic test for the evaluation of penile arterial insufﬁciency.33 Previous
studies have conﬁrmed the sensitivity of PDU in the detection of
arterial insufﬁciency in patients with various medical vascular
diseases and those with risk factors for vascular diseases.33–35 In
the Mayo Clinic series, PDU examination with PSV less than 25 cm/s
was found to have a sensitivity of 100% and a speciﬁcity of 95% forthe diagnosis of severe systemic arterial disease in the same patients
implicating the potentially important role of atherosclerosis.35
In this investigation we hypothesized that ED in men with
epilepsy may have a vascular etiology. To our knowledge, no
previous studies have directly investigated the presence of
vasculogenic ED in men with epilepsy. PDU was used to assess
the status of penile blood ﬂow. We also measured the intima-
media thickness of the carotid (CA-IMT) arteries using Duplex
Ultrasonography, a sensitive method for detection of early cerebral
and systemic atherosclerosis.36 Patients with normal and abnor-
mal penile arterial blood ﬂow ﬁndings were compared in relation
to scores of erectile function; demographic-, clinical-, hormonal-
and vascular-related risk variables including CA-IMT. The rela-
tionship between CA-IMT values and PDU variables was also
determined.
2. Materials and methods
We approached 100 adult men with epilepsy to participate in
this study and 47 ultimately agreed to undergo PDU examination.
Participating subjects ranged in age between 20 and 48 years and
duration of illness ranged from 3 to 35 years. Seizure types were
diagnosed according to the International League Against Epilepsy
(ILAE) criteria.37 Patients were recruited from the out-patient
epilepsy clinic of the Department of Neurology and Psychiatry of
Assiut University Hospital, Assiut, Egypt (over a period of one year).
All patients were compliant with treatment with conventional
AEDs [CBZ or VPA monotherapies or polytherapy (CBZ + VPA)] for
at least 6 months before participation in the study. Twenty-ﬁve
healthy men matched for age- (range: 20–48 years; mean:
30.36  7.59), educational level and socioeconomic status were also
included for comparisons. Control subjects were chosen from the
patients’ healthy relatives who agreed to undergo PDU exam.
Excluded were subjects (patients and controls) with any of the
following: (1) history of neurological disorder other than epilepsy
likely to affect erectile function, (2) concomitantly known vascular
risk or manifest atherosclerotic vascular disease [e.g. heavy
smoking, diabetes mellitus (DM), hypertension (HTN), hypercho-
lesterolemia/dyslipidemia, hyperuricemia, coronary artery disease
(CHD) such as angina pectoris or myocardial infarction (MI)], heart
failure, cerebrovascular stroke or transient ischemic attacks (TIAs),
(3) history of systemic illness unrelated to vascular disease likely to
affect erectile function (e.g. renal failure, serum creatinine
concentration >150 mmol/l, chronic hepatic illness), (4) history
of clinically signiﬁcant genitourinary disease, pelvic trauma, pelvic
surgery, or radiation therapy, (5) alcoholism or diagnosed
substance abuse and/or previous hospitalization for substance
abuse, (6) use of any regular medication(s) in addition to AEDs (e.g.
antihypertensive drugs, heart medications, antidepressants, tran-
quilizers, and sedatives), and (7) current or recent treatment of ED
with intracorporeal injection or application of vasoactive drugs.
The study protocol was approved by the Ethical Committee of
the Faculty of Medicine of Assiut University, Assiut, Egypt and all
patients and control subjects gave their informed consents to
participate in this study.
All patients and healthy subjects underwent the same research
protocol, which included the procedures described below.
2.1. Medical, neurological, endocrinological, psychiatric, vascular and
urological histories and examinations
Seizure variables included age at onset, precipitating factors,
duration of illness, seizure type, seizure frequency, family history of
epilepsy, AED(s) (monotherapy or polytherapy), duration of
treatment, degree of seizure control on AED(s) and side effects of
medications. Seizure frequency was deﬁned as24: (a) very frequent:
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month, (b) frequent: occurring at intervals longer than 7 days but
shorter than 30 days per month, (c) occasional: occurring at intervals
longer than 30 days per month but shorter than one year, and (d)
rare: occurring at intervals longer than one year. Regarding the
degree of control on AEDs, patients were considered controlled on
AEDs, when seizure free for 1 year, partially controlled when
seizure frequencies were occasional and uncontrolled when seizures
were frequent or very frequent.
Patients with ED underwent a urological exam as part of the
routine testing in the out-patient clinic of the Urology Department.
All patients underwent standard electroencephalography (EEG)
and neuroimaging [as computed tomography (CT) or magnetic
resonance imaging (MRI) of the brain].
2.2. Assessment of erectile function
Assessment of erectile function was undertaken using the
Arabic translated version38 of the International Index of Erectile
Function Questionnaire 5-items version or IIEF-5.39 Four item of
IIEF-5 are scored from 0 to 5 and one item is scored from 1 to
5. Four of the 6 items include questions regarding maintenance
ability, erection conﬁdence, maintenance frequency, and erection
ﬁrmness, while the single item includes a question about
intercourse satisfaction and overall satisfaction. A cutoff value of
21 was chosen so that patients with IIEF-5 scores of 21 were
classiﬁed as having ED while scores >21 were not. According to
this scale, ED was classiﬁed into four categories including severe
ED (1–7), moderate ED (8–11), mild-to-moderate ED (12–16), mild
(17–21), and no ED (22–25).
2.3. Psychiatric evaluation
Clinical psychiatric interview and evaluation of patients was
done by a psychiatrist using the diagnostic criteria of Diagnostic and
Statistical Manual of Mental Health Disorders (4th edition) or DSM-
IV.40 Differentiation between psychiatric symptoms and disorders
was made by clinical judgment. In patients with coexisting
symptoms, a trained psychologist (under supervision of the
psychiatrist) administered Arabic translated questionnaires includ-
ing the Beck Depression Inventory (2nd edition) (BDI-II)41,42 and
Hamilton Anxiety Rating Scale (HAM-A)43,44 to screen and assess the
severity of psychiatric symptoms. The BDI-II consists of 21 items,
each item corresponding to a symptom of depression, and one sums
across items to yield a single overall score. Accordingly, subjects
were divided into: (a) no or minimal symptoms (score ranging from
0 to13), (b) mild depressive symptoms (score ranging from 14 to 19),
(c) moderate depressive symptoms (score ranging from 20 to 28),
and (d) severe depressive symptoms (score ranging from 29 to 63).
The HAM-A consists of 14 items, each scored on a 5-point scale,
ranging from 0 (not present) to 4 (severe). Accordingly, subjects
were divided into: (a) no symptoms (score ranging from 0 to 13), (b)
mild anxiety symptoms (score ranging from 14 to 17), (c) moderate
anxiety symptoms (score ranging from 18 to 24), and (d) severe
anxiety symptoms (score ranging from 25 to 30).
2.4. Laboratory investigations
Study procedures included control for timing of blood sampling
which were withdrawn at 8.00–10.00 am after an overnight fast
and being seizure free for at least 72 h (as any postictal central
neurochemical dysfunction, is recognized to reverse within hours).
The following laboratory tests were completed: (a) standard tests
which included complete blood count (CBC) and serum concen-
trations of creatinine, liver enzymes and fasting blood glucose,
and (b) speciﬁc tests which included measurements of serumconcentrations of free testosterone, prolactin, free thyroxin (FT4),
thyroid stimulating hormone (TSH) and sex hormone binding
globulin (SHBG). Assessment protocols were performed according
to the recommendations of the manufacturers. The concentrations
of serum prolactin, FT4 and TSH were measured by IMMULITE
reproductive hormone assays from Diagnostic Product Coopera-
tion (Los Angeles, USA). The concentrations of free testosterone
were measured by enzyme immunoassay method (ELISA) (Bio-
Source Europe S.A. Rue de I’Industrie, 8-B-1400 Nivelles, Belgium)
and SHBG concentrations were measured by ELISA kits (IBL
International GMBH, Hamburg, Germany). Concentrations were
assessed in close temporal proximity to the clinical evaluation and
interview of patients. Serum levels of AEDs were measured as part
of the investigation in batched assays through Therapeutic Drug
Monitoring (TDM) Laboratory of Assiut University Hospital, Assiut,
Egypt, using Fluorescence Polarization Immunoassay System of
Abbott, TDxFLX apparatus (Abbott Lab, Wiesbaden, Germany). The
approximated reference therapeutic serum levels of CBZ are
4–10 mg/ml and 50–100 mg/ml for VPA.24
2.5. Assessment of penile blood ﬂow status
PDU with intracavernous injection (ICI) of prostaglandin E1
(PGE1) was performed (by the specialized radiologist) in a private
room that was partially lighted and slightly warmed. A short
history was taken from the patient and the entire procedure was
explained in clear words by the experienced radiologist. The
equipment used was the GE Logic Three Color Doppler Machine
(GE L3-India). This equipment has a short foot print linear
transducer (5–10 MHz). The procedure was done while the patient
was in supine position. Sterilization of the shaft of the penis and a
light tronique was applied to the root of the penis with light
tightness before the injection. The corpus spongiosus was clinched
before the injection to protect the urethra. Prostaglandin E1 (PGE1)
(alprostadil) in a dose of 5–15 mg was carefully given while the
needle (28 gauge short needle or insulin injection needle) was in a
perpendicular direction at the lateral aspect of the mid shaft of the
penis and away from the site of the urethra and dorsal nerve of the
penis. The tourniquet was then removed. Alprostadil was formed
of PGE1 precipitate added to 60 mg papaverine and 24 ml Ringer’s
solution and used as 0.5–1 ml dose. The initially used dose was
adapted to the history of the patient and reduced in the presence of
suspected psychogenic ED for fear of occurrence of prolonged
erection or priapism. The patient was then allowed to perform
tactile self-genital stimulation in privacy (to prevent the inhibitory
effect of sympathetic activity and optimize penile vascular and
corporeal smooth muscle relaxation) for about 5–10 min to attain
full and best quality erection and obtain the most reliable dynamic
vascular response by PDU. The erectile response was periodically
evaluated for both rigidity and duration. All patients were
questioned regarding the erectile response to vasoactive agents
during PDU compared to erections achieved at home in private to
assess levels of test-associated anxiety. If there was no signiﬁcant
difference in the quality of erection, we did not re-dose to achieve
maximal cavernosal arterial and smooth muscle relaxation. If there
was difference in the degree of erectile quality, we performed
second intracavernous injection and sexual stimulation.
PDU Doppler spectral wave form traces were obtained at
20 min intervals after full erection and not obtained in the ﬂaccid
state as the latter has been proven to be inaccurate in the
functional evaluation of the penile vascular system. In the ﬂaccid
state, the cavernous smooth musculature and the smooth muscles
of the arteriolar and arterial walls of the penile tissue are tonically
contracted, allowing only a small amount of arterial ﬂow for
nutritional purposes. Therefore, PDU examination was conducted
only in the full erection state. The examination began by gray scale
Table 1
Demographic and clinical features of the sample.
Age; years 20–48 (30.98  6.82)
Body mass index (BMI); kg/m2 9–34 (23.69  3.69)
Systolic blood pressure (SBP); mmHg 90–170 (123.66  15.09)
Diastolic blood pressure (DBP); mmHg 60–130 (76.91  9.72)
Age at onset of disease; years 1–35 (16.83  8.21)
Duration of illness; years 3–35 (13.98  7.06)
Type of seizures:
GTC 22 (46.81%)
Complex partial/Partial epilepsy with
secondary generalization
25 (53.19%)
AED(s) utilized
CBZ 18 (38.30%)
VPA 14 (29.79%)
Polytherapy 15 (31.91%)
Dose of AED(s) utilized; mg/day
CBZ 400–1200 (738.46  389.8)
VPA 200–1400 (777.27  502.4)
Duration of treatment; years 3–16 (9.65  3.05)
Serum drug level; mg/ml
CBZ 3.5–11.9 (8.14  3.6)
VPA 30.04–102.60 (70.74  35.0)
Degree of control on AED(s)
Controlled 5 (10.64%)
Partially controlled 3 (6.38%)
Uncontrolled 39 (82.98%)
Values are expressed as mean  SD and number (%).
GTC, generalized tonic-clonic; AEDs, antiepileptic drugs; CBZ, carbamazepine; VPA,
valproate.
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mas or tunical ﬁbrosis. Color ﬂow mapping was performed to
assess the anatomy of the cavernosal arteries, location and
variations.
The penile peak systolic blood ﬂow velocity (PSV), end-diastolic
blood ﬂow velocity (EDV) and the resistance index (RI) of
cavernosal arteries from each side (right and left) were recorded.
Measurements from both sides were summated and the mean of
the two sides was recorded and used for ﬁnal statistical analysis if
asymmetrical cavernous arterial ﬂows greater than 10 cm/s were
not identiﬁed between both sides.34 Accordingly, if the person
achieved an erection as good or better than his erectile capacity at
home, a PSV > 35 cm/s was considered indicative of normal penile
arterial system, borderline if PSV was 25–35 cm/s and with arterial
insufﬁciency if PSV was <25 cm/s. In general, during normal
erections when inﬂow is increased, there should be no signiﬁcant
outﬂow of blood from the penis. If this portion of the test was
normal and the end-diastolic ﬂow was zero or less, the patient was
considered not to have an outﬂow problem. If there was an outﬂow
leak, the EDV was greater than zero. An EDV > 5 cm/s and
RI < 0.95 were considered diagnostic for venous leak. It was
possible for patients to have a combination of arterial insufﬁciency
and venous leak.5
Observation of each patient, particularly those with good
erection was done for 0.5–3 h, to exclude the possibility of
priapism.
2.6. Evaluation of the CA-IMT
CA-IMT was undertaken using high resolution Echo Color
Doppler. Examination was performed manually with measure-
ments taken twice by the same radiologist using a 5 MHZ linear
transducer of a Color Duplex Flow Imaging System (Acuson 128 XP,
Acuson Corporation, Mountain View, CA, USA) which operates in
several modes: real time B, color Doppler and spectral Doppler
modes. CA-IMT was measured in a 1 cm segment proximal to the
dilatation of the carotid bulb, the area of bifurcation, and the
proximal part of the internal carotid artery.36 Measurements from
both sides were summated and the means were recorded.
2.7. Statistical analysis
Calculations were performed using SPSS, version 12.0. Data
were examined for normality using the Kolmogorov–Simirnov test.
The Student’s t test was used for comparison of means of normally
distributed parameters while Mann–Whitney U test was used for
comparison of non-normally distributed parameters (e.g. scores of
BDI-II and HAM-A and concentrations of free testosterone and
SHBG). To determine the relationship between PSV, EDV and RI and
CA-IMT, a multivariate analysis was undertaken using PSV, EDV
and RI values as the dependent variables. Bivariate correlations
were examined between dependent variables and the independent
variables or confounders (e.g. age, duration of illness, systolic blood
pressure, diastolic blood pressure, scores of IIEF-5, BDI-II, HAM-A
and CA-IMT) (r and p values). Independent variables which had no
signiﬁcant correlation with PSV, EDV and RI values were then
excluded. The model was adjusted for other confounders. For all
tests, values of P < 0.05 were considered statistically signiﬁcant.
3. Results
This epilepsy cohort consisted of 47 adult males with primary
epilepsy (mean age = 30.98  6.82 years, duration of ill-
ness = 13.98  7.06 years). Patients were treated with one or more
conventional AED(s) for a mean period of 9.65  3.05 years (range:
3–16 years). All patients had normal CT or MRI of the brain and all werewithout focal or pelvic abnormalities on urologic examination. Table 1
provides the demographic and clinical features of the sample. Thirteen
patients (27.66%, 13/47) had ED with marked lowering of the IIEF-5
(17.60  3.77 versus 22.98  2.30 for controls; P = 0.0001). Depression
was reported in 59.57% (28/47), mostly of severe degree (n = 15,
53.57%); mild in 28.57% (n = 8); moderate in 17.86% (n = 5). Table 2
shows erectile function scores and depression and anxiety scores in
relation to the type of epilepsy and AEDs and the degree of seizure
control. Compared to controls, lower scores of IIEF-5 and higher scores
of BDI-II were reported in patients with complex partial epilepsy/
partial epilepsy with secondary generalization with poor seizure
control on AEDs. Lower levels of free testosterone were reported with
CBZ (monotherapy or polytherapy). Higher levels of SHBG were
associated with polytherapy (CBZ + VPA). No signiﬁcant differences
were reported in the concentrations of prolactin (8.7  3.4 ng/ml
versus 9.2  3.6; P = 0.118), FT4 (0.39  0.10 ng/dl versus 0.46  0.29;
P = 0.651) and TSH (2.23  1.77 mIU/ml versus 2.55  0.96; P = 0.463).
Poor seizure control on AEDs was associated with higher scores of IIEF-
5, higher BDI-II, and lower levels of free testosterone and higher levels
of SHBG. Table 3 shows the results of PDU and CA-IMT in relationship to
epilepsy- and treatment-related variables. Compared to controls, lower
values of PSV were reported in patients with temporal lobe epilepsy,
left sided epileptic activity, and poorer seizure control on AEDs. Patients
had higher values of CA-IMT, particularly those taking CBZ and those
with poor seizure control. Eleven patients out of 13 with ED (84.62%, 11/
13) had abnormal PDU parameters suggesting vasculogic ED (PSV:
28.23  6.1 cm/s versus 52.29  14.55 for control subjects;
P = 0.0001 and 56.32  16.45 cm/s for patients with high PSV;
P = 0.0001). PDU results showed evidence of arterial insufﬁciency in
5 patients (45.45%) (Fig. 1B) while the remaining 6 (54.55%) had mixed
arterial insufﬁciency and venous leak as evidenced by low values of PSV
and RI and high values of EDV (Fig. 1C). One patient had atheroma in one
Table 2
Signiﬁcance between different studied groups in scores of erectile function, psychosocial- and hormonal-related variables in relationship to epilepsy- and treatment-related
variables.
Epilepsy-related variables IIEF-5 BDI-II HAM-A Free testosterone SHBG
Patients
Mean 21.82  4.15 16.08 14.68 57.75 95.28
Percentiles: 25th, 50th, 75th – 8, 16.5, 30 5, 13, 22.75 20, 30, 85 84, 106, 180
P1 0.053 0.001 0.764 0.031 0.008
Type of seizures
Generalized 22.48  3.40
P1 0.728 0.002 0.982 0.153 0.019
Complex partial/partial with
secondary generalization
21.34  4.59
P1 0.042 0.006 0.630 0.044 0.015
P2 0.082 0.779 0.515 0.423 0.733
AED(s) utilized
CBZ 20.50  4.96
P1 0.005 0.015 0.490 0.020 0.007
P3 0.022 0.692 0.171 0.913 0.506
P4 1.000 0.067 0.106 0.052 0.657
VPA 22.79  2.86
P1 0.375 0.057 0.321 0.068 0.039
P4 0.548 0.203 0.677 0.154 0.862
Polytherapy 23.02  3.34
P1 0.522 0.001 0.321 0.524 0.115
Degree of control on AED(s)
Controlled 23.55  2.16
P1 0.808 0.769 0.014 0.549 0.046
P5 0.188 0.062 0.148 0.551 0.660
P6 0.029 0.001 0.001 0.383 0.909
Partially uncontrolled 21.85  4.20
P1 0.200 0.058 0.861 0.156 0.031
P6 0.493 0.059 0.039 0.639 0.522
Uncontrolled 21.17  4.55
P1 0.012 0.0001 0.081 0.031 0.017
Control subjects
Mean 22.98  2.30 11.38 13.92 68.85 91.50
Percentiles: 25th, 50th, 75th – 6, 9, 12 6, 11, 15 24, 80, 97 80, 85, 110
ED, erectile dysfunction; IIEF-5, International Index of Erectile Function – 5 item version; AEDs, antiepileptic drugs; CBZ, carbamazepine; VPA, valproate; BDI-II, Beck
Depression Inventory – 2nd edition; HAM-A, Hamilton Anxiety Rating Scale, SHBG, sex hormone binding globulin.
Signiﬁcance: P1: patients versus controls; P2: complex partial/partial with secondary generalization versus generalized; P3: CBZ versus VPA; P4: polytherapy versus CBZ or
VPA; P5: partially controlled versus controlled; P6: uncontrolled versus controlled.
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Table 4 shows the differences between patients with high PSV
(52.29  14.55 cm/s, n = 36, 76.60%) and low PSV (28.23  6.10 cm/s,
n = 11, 23.40%) in relationship to demographic-, clinical-, psychosocial-
and vascular-risk factors. Patients with low PSV had lower IIED-5
scores, higher EDV, lower RI, higher diastolic blood pressure and higher
CA-IMT values. No signiﬁcant differences were identiﬁed between
patients with high and low PSV on the BDI-II or HAM-A. Correlations
between PDU values and demographic-, clinical-, psychosocial- and
imaging-confounders were shown in Table 5 which demonstrates
signiﬁcant correlations between PDU variables and the duration of
illness, BDI-II and HAM-A scores, and values of CA-IMT. In multivariate
analysis, the association between PDU parameters and values of
CA-IMT remained signiﬁcant even after adjustment of other
confounding variables as shown in Table 6.
4. Discussion
Men with epilepsy frequently experience poor sexual perfor-
mance or potency which is reﬂected in their reduced rates of
fertility and marital status. This is conﬁrmed in the present
investigation as we found a higher frequency of ED (27.66%) and
lower scores of erectile function testing.4,6–12,17 Previously,
psychogenic impotence was believed as the most common type
of ED with up to 70% of impotent men with epilepsy thought to
suffer from this condition.6,8,10–17 This belief has given way to therealization that most men with epilepsy and ED have mixed
functional (psychogenic) and metabolic (endocrinal) ED due to
disturbances in sex hormones caused by epilepsy itself and adverse
effects of antiseizure medications.4,6,10–17 However, given the
growing evidence of increased atherosclerotic risk in people with
chronic epilepsy,18–20,22–32 this work was designed to investigate
the possibility that abnormalities in penile blood ﬂow and
evidence for vasculogenic ED in patients with epilepsy.
The approach here was novel as it directly investigated the
status of penile blood ﬂow using the high-resolution PDU after
induction of erection by intracavernous injection of vasoactive
substance (e.g. alprostadil or PGE1). PDU is a sensitive, reliable,
relatively non-invasive and non-expensive method to assess penile
blood ﬂow state.33 Two major outcomes were derived from this
study: (1) penile arterial insufﬁciency is not infrequent in men
with epilepsy with ED, and (2) men with chronic epilepsy
presented with objective evidence of atherosclerotic risk demon-
strated by increased values of CA-IMT which was signiﬁcantly
correlated with the abnormalities of penile blood ﬂow suggesting
that a vasculogenic element of ED may be related to systemic
atherosclerotic risk. Details of these ﬁndings follow below.
First, our ﬁndings indicate that penile arterial insufﬁciency is
common in men with epilepsy with ED suggesting that the
problem may be of vasculogenic origin. Nearly 23.40% (n = 11) of
the sample of men with epilepsy had either penile arterial
insufﬁciency alone (10.63%, n = 5) as evidenced by low PSV or a
Table 3
Results of Penile Duplex Ultrasonography (PDU) and carotid artery intima media thickness (CA-IMT) in relation to epilepsy- and treatment-related variables.
Epilepsy-related variables PSV (cm/s) EDV (cm/s) RI CA-IMT (mm)
Patients 16.83–113.78 17.34–12.07 0.60–1.70 0.4–1.0
48.63  19.00 3.68  4.90 1.06  0.12 0.65  0.13
P1 0.110 0.406 0.962 0.001
Type of seizures
Generalized 55.00  20.23 5.53  5.43 1.09  0.10 0.63  0.13
P1 0.560 0.821 0.429 0.063
Complex partial/partial
with secondary generalization
44.84  20.03 3.43  3.83 1.07  0.10 0.69  0.14
P1 0.009 0.360 0.741 0.001
P2 0.116 0.332 0.561 0.442
AED(s) utilized
CBZ 56.16  27.72 4.05  3.59 1.05  0.14 0.69  0.12
P1 0.892 0.684 0.572 0.003
P3 0.884 0.556 0.301 0.332
P4 0.529 0.753 0.171 0.279
VPA 47.09  20.68 6.84  6.55 1.12  0.14 0.65  0.16
P1 0.168 0.639 0.166 0.248
P4 0.770 0.770 0.826 0.823
Polytherapy 46.03  21.07 4.49  4.82 1.11  0.15 0.64  0.10
P1 0.378 0.982 0.132 0.082
Degree of control on AEDs
Controlled 61.66  31.52 3.36  1.89 1.09  0.12 0.59  0.10
P1 0.895 0.354 0.595 0.639
Partially controlled 60.05  20.21 10.93  5.56 1.17  0.11 0.70  0.17
P1 0.354 0.059 0.033 0.128
P5 0.288 0.670 0.749 0.103
P6 0.724 0.034 0.368 0.271
Uncontrolled 44.73  20.82 4.02  4.38 1.07  0.12 0.67  0.10
P1 0.051 0.696 0.788 0.002
P6 0.208 0.077 0.206 1.000
Control subjects 52.29  14.55 4.07  5.65 1.04  0.14 0.56  0.12
Values are expressed as mean  SD.
IIEF-5, International Index of Erectile Function – 5 item version; BDI-II, Beck Depression Inventory – 2nd edition; HAM-A, Hamilton Anxiety Rating Scale; AEDs, antiepileptic drugs;
CBZ, carbamazepine; VPA, valproate.
Signiﬁcance: P1: patients versus controls; P2: complex partial/partial with secondary generalization versus generalized; P3: CBZ versus VPA; P4: polytherapy versus CBZ or VPA; P5:
partially controlled versus controlled; P6: uncontrolled versus controlled.
Fig. 1. (A) A patient with normal Penile Duplex Ultrasonography. (B) A patient with arterial insufﬁciency as evidenced by low peak systolic velocity. (C) A patient with mixed
arterial insufﬁciency and venous leak as evidenced by low PSV, high EDV and low RI. (D) A patient with atheroma of the internal carotid artery.
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Table 4
Difference between patients with high and low peak systolic velocity (PSV) in relation to demographic-, clinical-, laboratory-, psychosocial-and vascular-risk factors.
Demographic and clinical features Patients with high
PSV (>35 m/s)
(n = 36, 76.60%)
Patients with low
PSV (25–35 m/s)
(n = 11, 23.40%)
Controls P1-value P2-value P3-value
PSV; cm/s 56.32  16.45 28.23  6.10 52.29  14.55 0.381 0.0001 0.0001
IIEF-5 22.73  2.66 20.86  3.24 22.98  3.37 0.310 0.034 0.122
EDV; cm/s 5.05  4.18 2.22  5.71 3.87  5.60 0.460 0.004 0.001
RI 1.08  0.12 0.89  0.22 1.04  0.14 0.251 0.071 0.010
Age; years 31.57  6.57 31.14  8.97 30.36  7.59 0.484 0.874 0.653
Age at onset; years 16.93  10.28 13.66  10.49 – – – 0.390
Duration of illness; years 14.64  6.87 17.00  8.56 – – – 0.601
Type of seizures
GTC 16 (44.44%) 4 (36.36%) – – – –
Complex partial/focal with
secondary generalization
20 (55.56%) 7 (63.63%) – – – –
AEDs
CBZ 15 (41.67%) 3 (27.27%) – – – –
VPA 10 (21.74%) 4 (36.36%) – – – –
Polytherapy 11 (30.56%) 4 (36.36%) – – – –
Duration of treatment; years 10.29  3.41 9.29  3.09 – – – 0.571
Degree of control on AEDs
Controlled 3 (8.33%) 2 (18.18%) – – – –
Partially controlled 2 (5.56%) 1 (9.09%) – – – –
uncontrolled 31 (86.11%) 8 (72.73%) – – –
Body mass index (BMI); kg/m2 24.57  3.96 24.19  2.75 24.23  2.25 0.780 0.940 0.783
Systolic blood pressure (SBP);
mmHg
118.75  13.56 127.14  18.48 116.43  12.16 0.805 0.086 0.259
Diastolic blood pressure (DBP);
mmHg
75.00  10.69 80.95  14.46 71.54  6.89 0.528 0.021 0.284
CA-IMT; mm 0.64  0.13 0.67  0.11 0.56  0.12 0.007 0.005 0.004
BDI-II; mean (percentiles: 25th,
50th, 75th)
19.82 (8, 14, 24.25) 25.83 (11.5, 28, 40.5) 11.38 (6, 9, 12) 0.006 0.003 0.310
HAM-A; mean (percentiles: 25th,
50th, 75th)
15.88 (4, 15, 20) 14.42 (4.5, 10.5, 27.5) 13.92 (6, 11, 15) 0.655 0.972 0.744
Values are expressed as mean  SD and number (%).
IIEF-5, International Index of Erectile Function – 5 item version; PSV, peak systolic velocity; EDV, end diastolic velocity; RI, resistance index, CBZ, carbamazepine; VPA, valproate; CA-
IMT, carotid artery intima-media thickness; BDI-II, Beck Depression Inventory – 2nd edition; HAM-A, Hamilton Anxiety Rating Scale.
Signiﬁcance; P1: patients with high PSV versus controls; P2: patients with low PSV versus controls; P3: oatients with high PSV versus patients with low PSV.
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as evidenced by high EDV. All patients with low PSV had ED and
lower scores of IIEF-5 while those with high PSV had neither PDU
abnormalities nor ED. The superior sensitivity and speciﬁcity of
PDU over penile angiography has been reported by several
investigators,45,46 and even PSV has been considered by some as
the most accurate indicator of arterial disease.47 We suggest that
venous leak is secondary to penile arterial insufﬁciency, a
suggestion supported by the signiﬁcant correlations between
PSV and EDV and RI and between EDV and RI. This is further
supported by the ﬁnding that veno-occlusive dysfunction could be
induced by cavernosal ischemia in animal models.48
Second, our ﬁndings indicate that men with chronic epilepsy
exhibited objective increase in atherosclerotic risks as evidenced
by high values of CA-IMT.26 We previously reported that high
values of CA-IMT were associated with CBZ, a commonly used AED
worldwide. CBZ is an EI-AED that is principally metabolized in the
hepatic P450 system (CYP450). The P450 system has a multitude ofTable 5
Correlations between Penile Duplex Ultrasonography (PDU) values and demographic-, 
Age Duration of illness IIEF-5 BD
PSV 0.162 0.315 0.092 0
0.325 0.010 0.407 0.
EDV 0.086 0.264 0.115 0.
0.468 0.052 0.364 0.
RI 0.145 0.288 0.088 0
0.756 0.050 0.486 0.
PSV, peak systolic velocity; EDV, end diastolic velocity; RI, resistance index; IIEF-5, In
Inventory-2nd edition; HAM-A, Hamilton Anxiety Rating Scale, SBP, systolic blood pressfunctions which include the synthesis and breakdown of endoge-
nous substances resulting in metabolic side effects.49 Several
cross-sectional and prospective studies in patients with epilepsy
have demonstrated that long-term use of CBZ may result in an
adverse vascular risk proﬁle.18–32 We also reported that patients
who were lacking control on AEDs had higher values of CA-IMT
(which reﬂect the longer duration of illness, longer-term treatment
with AEDs and use of combination therapy).26
Furthermore, the ﬁnding that patients with lower PSV had
higher values of diastolic blood pressure compared to control
subjects, the higher CA-IMT compared to patients with high PSV
values and the signiﬁcant correlation between CA-IMT and PSV,
EDV and RI in multivariate analysis, all suggesting that a
vasculogenic element of ED may be related to systemic athero-
sclerotic risk in the same group of patients independent of other
potential confounders.
The hypothesis that ED in men with epilepsy may be caused by
penile vascular abnormalities is not surprising due to the followingclinical-, psychosocial- and imaging variables.
I-II HAM-A SBP DBP CA-IMT
.299 0.253 0.079 0.125 0.344
050 0.054 0.358 0.454 0.014
286 0.347 0.090 0.095 0.505
054 0.015 0.334 0.206 0.0001
.304 0.280 0.119 0.179 0.490
050 0.052 0.269 0.214 0.0001
ternational Index of Erectile Function – 5 item version; BDI-II, Beck Depression
ure; DBP, diastolic blood pressure; CA-IMT, carotid artery intima-media thickness.
Table 6
Multivariate analysis between carotid artery intima media thickness (CA-IMT) and
parameters of Penile Duplex Ultrasonography (PDU).
Multivariate analysis
Odd’s ratio (OR)
95% conﬁdence interval (95% CI)
PSV EDV RI
2.90a,b,* 2.55a,b,* 2.05a,b,*
1.20 to 6.80 1.04–6.80 1.03 to 5.14
3.86a,b,** 4.50a,b,** 3.55a,b,**
1.23 to 9.80 1.54–13.2 1.23 to 8.80
a Adjusted for duration of illness.
b Adjusted for duration of illness, BDI-II and HAM-A. PSV, peak systolic velocity;
EDV, end-diastolic velocity; RI, resistance index; BDI-II, Beck Depression Inventory-
2nd edition; HAM-A, Hamilton Anxiety Rating Scale.
* P < 0.05.
** P < 0.01.
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which is closely related to systemic vasculature, affected by
various vascular risk factors and atherosclerosis and its diseases.
For example, hypertension is a well-recognized risk factor for
arteriosclerosis with a prevalence of about 45% in one series of
impotent men. In patients with hypertension, an increase in
peripheral vascular resistance and alteration in the vessel
architecture may result in an increase in wall-to-lumen ratio
and reduction in dilatory capacity which may contribute to
impotence with hypertension.45 In diabetes mellitus, ED has been
reported in 35–75% of men. In diabetic men with ED, a PDU study
after intracavernous injection of PGE1 revealed a high prevalence
(>75%) of penile arterial insufﬁciency and pathologic change in the
cavernous arteries.35 Hyperlipidemia, a well-known risk factor for
atherosclerosis, enhances the deposition of lipid in the vascular
lesions and causes atherosclerosis and eventual occlusion. The
atherosclerotic lesions can extend to the internal pudendal or
cavernous arteries to reduce inﬂow. Ultrastructural studies of
cholesterol-fed rabbits have also revealed early atherosclerotic
changes in the corpus cavernosum,50 (2) recent studies indicated
that the IMT of the cavernous intima-media thickness has a strong
direct correlation with the IMT of the carotid and femoral
arteries.51
Although not our aim, but as hypothesized and in accord with
previous studies, we found that patients with epilepsy had a higher
frequency of depression (59.57%), mostly of a severe degree
(53.57%). Scores of IIEF-5 were found to be signiﬁcantly correlated
with BDI-II and HAM-A.12–17 The ﬁnancial stress, poor cultural
approach to epilepsy, unemployment and inability to drive, all
result in low self-esteem, lessened well-being, social isolation,
stigmatization, psychiatric abnormalities, hyposexuality and poor
quality of life. We also reported lower levels of free testosterone
with CBZ (monotherapy or polytherapy) and higher levels of SHBG
with polytherapy (CBZ + VPA).4,6 It is well known that testosterone
enhances sexual interest, increases frequency of sexual acts, and
increases the frequency of nocturnal erections. Higher levels of
SHBG would be expected to produce sexual dysfunction by
decreasing the serum levels of free testosterone and/or albumin
bound testosterone. SHBG is the most important regulator for the
biologic effect of the testosterone on the target tissue (i.e. it
decreases the activity of the testosterone on the target cells52).
The main strength of this study is that it is the ﬁrst to directly
investigate patients with epilepsy for the presence of a vascular
element for ED. However, this study also has limitations: (1) the
number of patients is relatively small. Nevertheless, the limited
sample size is not likely to detract from the validity of our main
ﬁndings. The present investigation may be considered a preliminaryhypothesis for further examination in larger population-based
samples, (2) ED in men is a disorder of high prevalence ranging from
2 to 18.9% in younger men (25–40 years in age) according to different
population studies, and up to 50–80% of men over age of 40, even
reaching as high as 86% in men 80 years and older.53 Hence, the
frequency of ED might be increased among patients with epilepsy
compared to the general population, (3) repeated measurements
were not made to account for within-individual variability in the
PDU measurements, single measurements may be defensible
given the relatively invasive nature of the method. This is
exempliﬁed by the fact that 53% of our original sample of patients
refused to do PDU exam with intracavernous injection of PGE1, (4)
given the cross-sectional design of this study, the temporal
relationship between the increase in changes in vascular risk
factors and changes in the penile arterial blood ﬂow and vascular
wall changes of the carotid arteries and the onset of epilepsy
remain unknown. (5) Some authors suggested that although
cavernous PSV is generally considered a major parameter in
evaluation of penile arterial blood ﬂow, it can be associated with
false positives and negatives because of anatomic variations of the
cavernous artery, the insufﬁcient characterization of an early
phase of vascular disease and the inﬂuence of adrenergic tone.54
5. Conclusions
Vasculogenic ED appears to be frequent in men with epilepsy
and its relationship to systemic atherosclerosis cannot be
excluded. The results of this study may have implications for
early prevention and direct interventions including medical
treatments. Medical treatment such as antidepressants, vasodila-
tors and folate and vitamin supplements may be needed for severe
conditions to improve the overall quality of life of patients with
epilepsy.
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